The Future of Monoclonal Antibodies Therapeutics: Innovation in antibody engineering, key growth strategies and forecasts to 2011

Table of Contents

Executive Summary

• Introduction
• Antibody engineering and innovation in the market
• The current monoclonal antibody market
• The antibody pipeline and forecasts to 2011
• Competitive landscape and future growth strategies

Chapter 1 Introduction

• Summary
• Introduction
• History of monoclonal antibodies
• Monoclonal antibody approval process
• Current approval process
• Biogeneric regulations
• Key trends in the market
• Advancements in innovation
• Diversification of therapy areas
• Big Pharma entering the mAb market

Chapter 2 Antibody engineering and innovation in the market

• Summary
• Introduction
• The move from murine to fully human mAbs
• Whole IgG monoclonal antibodies
  • Murine
  • Chimeric
  • Humanized
  • Human
• Innovations in antibody structures
  • Fab fragments
  • Single chain variable fragments
• Extended release formulations
• Innovation in antibody conjugation
• Types of conjugation
  • Direct arming: antibody conjugation
  • Indirect arming: Bispecific monoclonal antibodies
  • Pre-targeting
• Marketed conjugated monoclonal antibodies
• Conjugation technology
  • Seattle Genetics antibody technology
  • ImmunoGen mAb technology
  • Peregrine mAb technology
• Enhancing monoclonal antibody potency
• Drug discovery
• Cambridge Antibody Technology
• Dyax
• Morphosys
• Innovation in drug delivery
• Drug delivery devices
• Inhaled monoclonal antibodies
• Oral monoclonal antibodies

Chapter 3 The current monoclonal antibody market

• Summary
• Introduction
• Strategic analysis
• Drivers
  • Pipeline drugs
  • Immature market
  • Big Pharma entering the mAb market
  • High level of innovation
  • Approval of new indications
  • Combination therapies
• Resistors
  • Publicized side effects
  • Drugs suspended from market
  • Competition from small molecule drugs
  • Pricing and reimbursement schemes
• Analysis of launched drugs
• Oncology
  • Rituxan
  • Herceptin
  • Avastin
  • Erbitux
  • Campath
  • Zevalin
  • MyloTarg
  • Bexxar
• AIID
  • Remicade
  • Humira
  • Raptiva
  • Simulect
  • Zenapax
  • OrthoClone OKT3
• Hemostasis
  • ReoPro
• Anti-infectives
  • Synagis
• Respiratory
  • Xolair
• Marketed monoclonal antibody forecasts

Chapter 4 The antibody pipeline and forecasts to 2011

• Summary
• Introduction
• Strategic analysis
• Opportunities
• Clinical trials
  • Erbitux and Avastin
  • Simulect, Zenapax and Campath
  • Campath
  • Others
• Innovation in antibody engineering
• New indications
• Challenges
• Generic biologics
• Adverse reactions in clinical trials, side effects and termination of
• development
• High attrition rates
• Analysis of pipeline drugs
• AIID
  • Cimzia
  • MRA/Actemra
  • Eculizumab
  • AMG-162
• Cardiovascular
  • Pexelizumab
• Infectious diseases
  • Numax
• Oncology
  • ABX-EGF
  • MDX-010+MDX-1379
  • Humax
• Ophthalmology
  • Lucentis
• Late stage pipeline forecasts
• The antibody market in 2011

Chapter 5 Competitive landscape and future growth strategies

• Summary
• Introduction
• Key players in the monoclonal antibody market
• M&A and licensing activity
• Big Pharma acquiring biotechs and antibody companies
  • AstraZeneca and CAT
  • Novartis and NeuTec
  • Amgen and Abgenix
  • Roche and GlycArt
  • MedImmune and Cellective Therapeutics
  • Pfizer and Bioren
• Company profiles
• Big Pharma
• Roche
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline
• Novartis
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline
• Pfizer
  • Company overview
  • Strategic and growth analysis
  • Pipeline
• Large biotech
• Genentech
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline
• MedImmune
  • Company Profile
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• Biogen Idec
  • Company overview
  • Strategic analysis
  • Marketed products
  • Pipeline products
• UCB-Celltech
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• Small biotech/antibody companies
• Medarex
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• XOMA
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• Technology companies
• BioWa
  • Company overview
  • Strategic and growth analysis
  • Pipeline products
• Crucell
  • Company overview
  • Strategic and growth analysis
  • Pipeline products

Chapter 6 Appendix

• Sales data
• Index